Pricing Log in Create free account
Saturday 17 October 2026 Export BFRI’s income statement to Excel — free account

Biofrontera Inc.

BFRI Healthcare Drug Manufacturers Specialty & Generic

Biofrontera Inc.’s revenue for fiscal 2025 (year ended December 2025) was $41.7 million, up 11.7% from fiscal 2024. In the quarter to June 2026, revenue grew 32.9%, EPS grew 91.2%, free cash flow grew 45.6% and total debt rose 6.50%, each against the same quarter a year earlier. Revenue growth for five consecutive years.

0.82 0.03 −3.53%
Market cap
$12.6M
P/E
0.0×
Fwd P/E
−4.1×
Dividend yield
—
F-score
3/9
Altman Z
−5.67
Beneish M
0.02
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 0.65%

Capital & Financial Ratios $m

Market Cap 12.58
Revenue 46.17
Net Income (6.36)
Free Cash Flow (7.93)
Net Debt (0.05)
Current Ratio 1.18
Debt/Equity 0.78
P/E ratio 0.00
Fwd P/E (4.07) (negative: loss-making)
P/S ratio 0.23
P/B ratio 1.78
Past 5Y EPS Growth —
This Y EPS Growth 62.50% (at or above 15%: strong)
Next Y EPS Growth 151.28% (at or above 15%: strong)
Next Y revenue growth 10.66% (at or above 10%: strong)
Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 0.2×, against a ten-year median of 0.1×; over the ten years it ranged from −0.4× in 2023 to 2.5× in 2021.
P/S against its own 10 years 44.46%
10-year low 10-year high
P/B against its own 10 years 59.19%
10-year low 10-year high
EV/Sales against its own 10 years 64.58%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 1 6 6 5
Receivables 5 5 7 6
Inventory 11 7 1 1
Other 5 2 1 0
23 21 18 12
2023 2024 2025 Q'26
Payables 9 7 7 5
ST’ Debt 4 — — —
Other — — — —
18 12 12 11

Compound Annual Growth %

10y 5y 3y
Sales — 17.21% 13.30%
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — 12.45% (24.00%)

Revenue $m

Mar Jun Sep Dec Year
’26 10 12 — — —
’25 9 9 7 17 42
’24 8 8 9 13 37
’23 9 6 9 11 34
’22 10 4 4 10 29
’21 5 6 4 9 24
’20 5 2 3 — 19
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 0 (2) — — —
’25 (4) (3) (4) (2) (13)
’24 (3) (5) (1) (1) (10)
’23 (4) (10) (2) (9) (25)
’22 (2) 0 (6) (8) (16)
’21 (3) (1) (1) (21) (27)
’20 (7) (4) (12) (1) (12)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 0 (2) — — —
’25 (4) (3) (4) (2) (13)
’24 (3) (5) (1) (1) (10)
’23 (4) (10) (2) (9) (25)
’22 (2) 0 (6) (8) (16)
’21 (3) (1) (1) (21) (27)
’20 (7) (4) (12) (1) (12)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (0.41) (0.05) — — —
’25 (0.47) (0.57) (0.62) 0.63 (1.04)
’24 (2.88) (0.05) (0.98) 0.69 (3.22)
’23 (5.60) (7.23) (4.64) 1.65 (13.02)
’22 6.40 (1.00) (2.20) (2.80) (0.60)
’21 (8.83) (9.15) (40.00) (25.80) (85.60)
’20 (0.34) (0.31) (59.70k) — (9.59k)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low — — — — — 45.00 15.00 2.66 0.61 0.54

Analyst estimates 2026–2028

Powerpack
High — — — — — 292.60 147.60 22.40 3.90 1.87
People
People Employees — — — — 56 69 81 85 93 94
Revenue/emp, $m — — — 0.00 0.34 0.35 0.35 0.40 0.40 0.44
Income, $m
Income, $m Revenue — — — 26 19 24 29 34 37 42
Gross margin, % — — — 50.06 51.90 47.13 47.04 48.80 50.14 73.71
EBT — — — (11) (11) (38) (1) (20) (18) (11)
EBT margin, % — — — (41.82) (57.95) (156.25) (2.12) (59.04) (47.53) (25.20)
Net income — 0 — (11) (11) (38) (1) (20) (18) (11)
Depreciation — — — 1 1 1 1 1 1 1
Per share, $
Per share, $ Revenue — — — 43.13 17,135.45 54.72 27.13 22.03 6.77 4.10
Earnings — — — (18.09) (9,589.35) (85.60) (0.60) (13.02) (3.22) (1.04)
Cash flow — — — (62.07) (11,244.55) (60.66) (15.33) (16.10) (1.86) (1.31)
Capex — — — 0.00 0.00 (0.02) (0.04) 0.00 (0.01) 0.00
Free cash flow — — — (62.07) (11,244.55) (60.69) (15.36) (16.10) (1.87) (1.31)
Book value — — — (49.72) 5,298.18 25.74 22.59 3.10 0.80 1.03
Shares, m — — — 1 0 0 1 2 6 10
Valuation, ×
Valuation, × P/E — — — 0.00 0.00 0.00 28.17 0.00 0.00 0.00
P/S — — — 1.94 1.94 2.75 0.62 0.13 0.16 0.14
P/B — — — 0.00 0.00 5.84 0.75 0.90 1.36 0.55
EV/Sales — — — 1.85 1.85 1.73 (0.30) 0.22 0.12 0.10
EV/FCF — — — (5.25) (5.25) (1.56) 0.53 (0.30) (0.44) (0.32)
Cash, $m
Cash, $m Operating cash flow — — — (38) (12) (27) (16) (25) (10) (13)
Capex — — — (1) — 0 0 0 0 0
Free cash flow — — — (38) (12) (27) (16) (25) (10) (13)
Balance, $m
Balance, $m Working capital — — — 12 15 33 22 5 9 6
Total debt — — — 38 — — 1 4 4 5
Net debt — — — 31 (8) (25) (26) 2 (2) (2)
Shareholders’ equity — — — (30) 6 11 24 5 4 10
Returns, %
Returns, % ROA — — — (76.39) (41.55) (97.50) (1.23) (51.08) (70.99) (41.59)
ROIC — — — 0.00 0.00 0.00 0.00 (194.79) (410.70) (81.82)
ROE — — — 90.20 90.24 (439.39) (3.63) (140.43) (384.98) (141.30)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Biofrontera Inc. vs peers in Drug Manufacturers Specialty & Generic (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
SHPH Shuttle Pharmaceuticals Holdings, Inc. $26.5M 0.2× — — n/m +82.01% (above 0%: growing) 0.00% 0.00% Compare
TXMD TherapeuticsMD, Inc. $22.3M — (loss-making) 18.9× −8.72% (below 0%: shrinking) −80.00% (below 0%: shrinking) +104.46% (above 0%: growing) 100.00% (93.90%) Compare
AYTU Aytu BioPharma, Inc. $21.8M — (loss-making) — (loss-making) +6.42% (above 0%: growing) n/m +57.72% (above 0%: growing) 64.63% (4.82%) Compare
UPC Universe Pharmaceuticals INC $20.9M — (loss-making) 4.1× −23.98% (below 0%: shrinking) −110.15% (below 0%: shrinking) −84.99% (below 0%: shrinking) 32.57% 0.00% Compare
BGXXQ Bright Green Corporation $13.9M — (loss-making) — — n/m −1.46% (below 0%: shrinking) 0.00% 0.00% Compare
BFRI Biofrontera Inc. $12.6M — (loss-making) — (loss-making) +32.92% (above 0%: growing) n/m +45.57% (above 0%: growing) 79.92% (4.37%)
INM InMed Pharmaceuticals Inc. $7.3M — (loss-making) — −26.22% (below 0%: shrinking) n/m −40.43% (below 0%: shrinking) 22.46% 0.00% Compare
APUS Apimeds Pharmaceuticals US, Inc. $6.6M — (loss-making) — — n/m −67.94% (below 0%: shrinking) — 0.00% Compare
SNOA Sonoma Pharmaceuticals, Inc. $5.5M — (loss-making) — (loss-making) +59.55% (above 0%: growing) n/m +69.31% (above 0%: growing) 40.23% (0.62%) Compare
Median of peers $17.4M — — −8.72% — +28.13% 32.57% 0.00%

All 86 Drug Manufacturers Specialty & Generic stocks →

Biofrontera Inc. (BFRI) key facts

  • Strength: Biofrontera Inc.’s revenue for fiscal 2025 (year ended December 2025) was $41.7 million, up 11.7% from fiscal 2024.
  • Biofrontera Inc. (BFRI) is a Drug Manufacturers Specialty & Generic company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, BFRI traded at $0.82, a market capitalization of $12.6 million.
  • Return on equity was −141.3% and debt-to-equity 0.78.
  • Its Piotroski F-score is 3 out of 9 and its Altman Z-score is −5.67 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Biofrontera Inc. (BFRI) Latest News

26 Feb

Impact 5 ·
stockrow.com/BFRI · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com